Sign up
Pharma Capital

ANGLE PLC opens up potential route to market for Parsortix platform

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), discusses with Proactive their significant new collaboration with healthcare giant Abbott Laboratories.

The two will be working on a metastatic breast cancer study.

Abbott will provide its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 US Food & Drug Administration (FDA) study for FISH (fluorescence in situ hybridization) analysis of circulating tumour cells (CTCs) in the form of a research grant.

FISH analysis, which is a form of investigation of the cancer cells used with solid tissue biopsy to help select treatment, is one of the exploratory end-points for ANGLE's FDA study in metastatic breast cancer

 

View full AGL profile View Profile
Newswire

ANGLE raises another £2.8mln

View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.